Addition of Bevacizumab to the existing standard of care was safe and showed promising overall results. The two- and three- year overall survival rates were 89.8 percent and 80.2 percent, respectively.
Fuente : http://www.eurekalert.org/pub_releases/2014-01/uoc...
Fuente : http://www.eurekalert.org/pub_releases/2014-01/uoc...